Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease
characterised by fibrosis of the lung parenchyma and loss of lung function. Although the …

Interstitial lung disease (ILD) encompasses a large and diverse group of pathological
conditions that share similar clinical, radiological and pathological manifestations, despite …

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a median survival time
from diagnosis of 2–3 years. Although the pathogenic pathways have not been fully …

BACKGROUND Interstitial lung disease (ILD) is a heterogeneous group of rare diseases
that primarily affect the pulmonary interstitium. Studies have implicated a role for telomere …

The proteomic analysis of bronchoalveolar lavage fluid (BALF) can give insight into
pulmonary disease pathology and response to therapy. Here, we describe the first gel-free …

Rationale Pulmonary fibrosis is a progressive disease with only few treatment options
available at the moment. Recently, the nucleoside uridine has been shown to exert anti …

Fibrotic remodeling is a process common to chronic lung diseases such as chronic
obstructive pulmonary disease (COPD), pulmonary fibrosis, acute respiratory distress …

The field of interstitial lung diseases (ILD) and especially idiopathic pulmonary fibrosis (IPF)
has undergone immense changes during the last ten to fifteen years. The process started …

Introduction: Nailfold capillaroscopy (NFC) is a non-invasive diagnostic test that is mostly
used for early diagnosis of collagen tissue diseases (CTDs). We aimed to evaluate whether …

Nintedanib is an intracellular inhibitor of tyrosine kinases that has recently been approved
as a treatment for idiopathic pulmonary fibrosis (IPF) by regulatory authorities in the USA …